Periodontitis is an inflammatory disease caused by microorganisms that induce the destruction of periodontal tissue. Inflamed and damaged tissue produces various inflammatory cytokines, which activate osteoclasts and induce alveolar bone loss and, eventually, tooth loss. Sirt6 expression suppresses inflammation and bone resorption; however, its role in periodontitis remains unclear. We hypothesized that Sirt6 has a protective role in periodontitis. To understand the role of Sirt6 in periodontitis, we compared periodontitis with ligature placement around the maxillary left second molar in 8-week-old control (C57BL/6J) male mice to Sirt6-overexpressing Tg (Sirt6Tg) mice, and we observed the resulting phenotypes using micro-CT. MDL801, a Sirt6 activator, was used as a therapy for periodontitis through oral gavage. Pro-inflammatory cytokines and increased osteoclast numbers were observed in alveolar bone tissue under periodontitis surgery. In the same condition, interestingly, protein levels from Sirt6 were the most downregulated among sirtuins in alveolar bone tissue. Based on micro-CT and CEJ-ABC distance, Sirt6Tg was observed to resist bone loss against ligature-induced periodontitis. Furthermore, the number of osteoclasts was significantly reduced in Sirt6Tg-ligated mice compared with control-ligated mice, although systemic inflammatory cytokines did not change. Consistent with this observation, we confirmed that bone loss was significantly reduced when MDL801, a Sirt6 activator, was included in the ligation mouse model. Our findings demonstrate that Sirt6 activation prevents bone loss against ligature-induced periodontitis. Thus, a Sirt6 activator may provide a new therapeutic approach for periodontitis.
13 January 2020 in Evidence-Based Complementary and Alternative Medicine
Background/Aims. Buyang Huanwu decoction (BHD) is a traditional Chinese and Korean herbal medicine prescription that has been widely used to treat various diseases including cerebral ischemia, gynecological disease, and neurological disorders. BHD is commonly used as a variable modified combination for synergistic therapeutic effects. However, the mechanism by which modified BHD (mBHD) produces anti‐inflammatory effects has not been elucidated yet. The purpose of this study was to develop mBHD with diminished potential side effects and verify its anti‐inflammatory effects. Methods. A cytotoxicity assay for BHD was performed using the MTT assay. Following treatment with BHD, mBHD‐1, and mBHD‐2 in the presence of lipopolysaccharide (LPS), nitric oxide (NO) secretion was detected in cell supernatants using a NO detection kit. The expression of proinflammatory mediators was detected using RT‐PCR and western blotting. To verify the mechanism of mBHD, specific inhibitors of JNK (SP600125) or p38 (SB203580) were used for co‐treatment with mBHD, and then the changes in NO and nitric oxide synthase (iNOS) were measured. Results. Both mBHD‐1 and mBHD‐2 showed greater anti‐inflammatory effects than BHD. Both mBHD‐1 and mBHD‐2 inhibited NO secretion and decreased the expression of IL‐1β, IL‐6, TNF‐α, and iNOS. Treatment with a p38 inhibitor and a JNK inhibitor in mBHD‐1‐ and mBHD‐2‐treated cells resulted in inhibition of NO and iNOS. Conclusion. We provided the first experimental evidence that mBHD may be a more useful anti‐inflammatory than BHD. High concentrations or long‐term use of BHD may be harmful to inflammatory status. Therefore, the length of treatment and concentration should be considered depending on the targeted disease.